文献速递前列腺癌

前列腺癌主动监测中首次随访活检阴性后的进展风险

Risk of progression following a negative biopsy in prostate cancer active surveillance.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-08-25

基于GAP3联盟24个中心13161例主动监测前列腺癌患者,比较首次随访活检阴性(27%)与阳性者的进展风险。阴性者转为主动治疗风险(aHR 0.45)、后续升级(aOR 0.52)和严重升级(OR 0.74)均更低,因影像数据有限未评估影像学进展。作者认为可考虑降低该组随访强度。

要点

  • 首次随访活检阴性者转为主动治疗风险较低:aHR 0.45(95%CI 0.42-0.49)。
  • 阴性者后续升级风险较低:aOR 0.52(95%CI 0.45-0.62)。

核心结论

  • 尽管随访方案存在异质性,这项全球研究显示首次活检阴性者较阳性者转为治疗、体积进展、任何升级和严重升级风险均降低。
  • 鉴于进展风险低且后续活检阴性可能性高,作者认为可考虑降低该组随访强度以减少不必要的侵入性活检。

研究设计与样本

  • 来自全球主动监测前列腺癌行动计划(GAP3)联盟数据库24个中心的13161例男性。
  • 纳入标准为基线分级组≤2、PSA≤20 ng/mL、cT分期1-2、1995年后诊断且至少1次随访活检。
  • 采用多变量混合效应生存回归评估转为治疗风险,采用混合效应二元逻辑回归评估体积进展、任何升级和严重升级的比值比(限至少2次监测活检者)。

主要发现

  • 27%的队列(n=3590)在首次活检时无前列腺癌证据,该组后续活检超过50%也为阴性。
  • 首次活检阴性者转为主动治疗风险较低:调整风险比0.45(95%CI 0.42-0.49)。
  • 首次活检阴性者后续任何升级风险较低:调整比值比0.52(95%CI 0.45-0.62)。
  • 因影像数据有限,未评估放射学进展。

临床怎么用

  • 作者认为,对于首次随访活检阴性的主动监测患者,可考虑降低随访强度以减少不必要的侵入性活检。

局限性

  • 随访方案存在异质性。
  • 因影像数据有限,未评估放射学进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently, follow-up protocols are applied equally to men on active surveillance (AS) for prostate cancer (PCa) regardless of findings at their initial follow-up biopsy. To determine whether less intensive follow-up is suitable following negative biopsy findings, we assessed the risk of converting to active treatment, any subsequent upgrading, volume progression (>33% positive cores), and serious upgrading (grade group >2) for negative compared with positive findings on initial follow-up biopsy. METHODS: 13,161 men from 24 centres participating in the Global Action Plan Active Surveillance Prostate Cancer [GAP3] consortium database, with baseline grade group ≤2, PSA ≤ 20 ng/mL, cT-stage 1-2, diagnosed after 1995, and ≥1 follow-up biopsy, were included in this study. Risk of converting to treatment was assessed using multivariable mixed-effects survival regression. Odds of volume progression, any upgrading and serious upgrading were assessed using mix-effects binary logistic regression for men with ≥2 surveillance biopsies. RESULTS: 27% of the cohort (n = 3590) had no evidence of PCa at their initial biopsy. Over 50% of subsequent biopsies in this group were also negative. A negative initial biopsy was associated with lower risk of conversion (adjusted hazard ratio: 0.45; 95% confidence interval [CI]: 0.42-0.49), subsequent upgrading (adjusted odds ratio [OR]: 0.52; 95%CI: 0.45-0.62) and serious upgrading (OR: 0.74; 95%CI: 0.59-92). Radiological progression was not assessed due to limited imaging data. CONCLUSION: Despite heterogeneity in follow-up schedules, findings from this global study indicated reduced risk of converting to treatment, volume progression, any upgrading and serious upgrading among men whose initial biopsy findings were negative compared with positive. Given the low risk of progression and high likelihood of further negative biopsy findings, consideration should be given to decreasing follow-up intensity for this group to reduce unnecessary invasive biopsies.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Beckmann K, Santaolalla A, Sugimoto M, et al. Risk of progression following a negative biopsy in prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 2022. PMID: 36008540. doi:10.1038/s41391-022-00582-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。